Literature DB >> 27626060

High-content molecular profiling of T-cell therapy in oncology.

Ruslan Novosiadly1, Michael Kalos1.   

Abstract

Recent clinical data have revealed the remarkable potential for T-cell-modulating agents to induce potent and durable responses in a subset of cancer patients. In this review, we discuss molecular approaches, platforms, and strategies that enable a broader interrogation of the activity of agents that modulate the activity of tumor-specific T cells, to more comprehensively understand how and why the agents succeed and fail, as well as examples of data sets generated in clinical trials that have provided important insights into the biological activity of T-cell therapies and that support further rational development of this exciting treatment modality.

Entities:  

Year:  2016        PMID: 27626060      PMCID: PMC5008264          DOI: 10.1038/mto.2016.9

Source DB:  PubMed          Journal:  Mol Ther Oncolytics        ISSN: 2372-7705            Impact factor:   7.200


  68 in total

1.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

2.  Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes.

Authors:  Evan W Newell; Natalia Sigal; Sean C Bendall; Garry P Nolan; Mark M Davis
Journal:  Immunity       Date:  2012-01-27       Impact factor: 31.745

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  An integrative paradigm to impart quality to correlative science.

Authors:  Michael Kalos
Journal:  J Transl Med       Date:  2010-03-16       Impact factor: 5.531

6.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

7.  Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations.

Authors:  David Tougeron; Emilie Fauquembergue; Alexandre Rouquette; Florence Le Pessot; Richard Sesboüé; Michèle Laurent; Pascaline Berthet; Jacques Mauillon; Frédéric Di Fiore; Jean-Christophe Sabourin; Pierre Michel; Mario Tosi; Thierry Frébourg; Jean-Baptiste Latouche
Journal:  Mod Pathol       Date:  2009-06-05       Impact factor: 7.842

8.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Authors:  Aaron P Rapoport; Edward A Stadtmauer; Gwendolyn K Binder-Scholl; Olga Goloubeva; Dan T Vogl; Simon F Lacey; Ashraf Z Badros; Alfred Garfall; Brendan Weiss; Jeffrey Finklestein; Irina Kulikovskaya; Sanjoy K Sinha; Shari Kronsberg; Minnal Gupta; Sarah Bond; Luca Melchiori; Joanna E Brewer; Alan D Bennett; Andrew B Gerry; Nicholas J Pumphrey; Daniel Williams; Helen K Tayton-Martin; Lilliam Ribeiro; Tom Holdich; Saul Yanovich; Nancy Hardy; Jean Yared; Naseem Kerr; Sunita Philip; Sandra Westphal; Don L Siegel; Bruce L Levine; Bent K Jakobsen; Michael Kalos; Carl H June
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

View more
  3 in total

1.  Next frontiers in CAR T-cell therapy.

Authors:  Christine E Brown; Prasad S Adusumilli
Journal:  Mol Ther Oncolytics       Date:  2016-11-30       Impact factor: 7.200

Review 2.  Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Authors:  Ciprian Tomuleasa; Shigeo Fuji; Cristian Berce; Anca Onaciu; Sergiu Chira; Bobe Petrushev; Wilhelm-Thomas Micu; Vlad Moisoiu; Ciprian Osan; Catalin Constantinescu; Sergiu Pasca; Ancuta Jurj; Laura Pop; Ioana Berindan-Neagoe; Delia Dima; Shigehisa Kitano
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

3.  Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells.

Authors:  Inez Johanna; Trudy Straetemans; Sabine Heijhuurs; Tineke Aarts-Riemens; Håkan Norell; Laura Bongiovanni; Alain de Bruin; Zsolt Sebestyen; Jürgen Kuball
Journal:  J Immunother Cancer       Date:  2019-03-12       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.